GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » EV-to-EBITDA

AMEUF (Anteris Technologies) EV-to-EBITDA : -3.38 (As of Jul. 21, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anteris Technologies's enterprise value is $138.09 Mil. Anteris Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-40.83 Mil. Therefore, Anteris Technologies's EV-to-EBITDA for today is -3.38.

The historical rank and industry rank for Anteris Technologies's EV-to-EBITDA or its related term are showing as below:

AMEUF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.24   Med: -2.14   Max: -0.22
Current: -1.53

During the past 13 years, the highest EV-to-EBITDA of Anteris Technologies was -0.22. The lowest was -3.24. And the median was -2.14.

AMEUF's EV-to-EBITDA is ranked worse than
100% of 496 companies
in the Medical Devices & Instruments industry
Industry Median: 15.95 vs AMEUF: -1.53

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-21), Anteris Technologies's stock price is $5.70. Anteris Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.750. Therefore, Anteris Technologies's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Anteris Technologies EV-to-EBITDA Historical Data

The historical data trend for Anteris Technologies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies EV-to-EBITDA Chart

Anteris Technologies Annual Data
Trend Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.70 -6.47 -7.28 -4.82 -1.73

Anteris Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -1.73 -2.13

Competitive Comparison of Anteris Technologies's EV-to-EBITDA

For the Medical Devices subindustry, Anteris Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's EV-to-EBITDA falls into.


;
;

Anteris Technologies EV-to-EBITDA Calculation

Anteris Technologies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=138.088/-40.831
=-3.38

Anteris Technologies's current Enterprise Value is $138.09 Mil.
Anteris Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies  (OTCPK:AMEUF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Anteris Technologies's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.70/-2.750
=At Loss

Anteris Technologies's share price for today is $5.70.
Anteris Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.750.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Anteris Technologies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies Business Description

Traded in Other Exchanges
Address
9 Sherwood Road, Level 3, Suite 302, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.